{"filings":[{"id":557077,"accession_number":"0001630627-26-000014","cik":1630627,"company_name":"TREACE MEDICAL CONCEPTS, INC.","ticker":"TMCI","form_type":"8-K","filed_at":"2026-05-20T21:30:15+00:00","items":["5.07","9.01"],"status":"ready","headline":"Treace Medical shareholders elect directors, approve exec compensation and auditor ratification","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors Lance Berry, Elizabeth Hanna, Jane Kiernan elected with over 30M votes each.","Advisory vote on executive compensation passed with 32.8M For vs 1.7M Against.","Ratification of Grant Thornton as auditor approved with 47.9M For vs 120.7K Against.","All three proposals passed at May 19, 2026 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":195267670.837931,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94215,"accession_number":"0001193125-26-213267","cik":1630627,"company_name":"TREACE MEDICAL CONCEPTS, INC.","ticker":"TMCI","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Treace Medical Q1 revenue falls 10% to $47.2M; net loss widens to $18.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $47.2M (-10% YoY); net loss $18.0M ($0.28 loss per share) vs $15.9M loss ($0.25) in Q1 2025.","Adjusted EBITDA loss of $5.5M vs $(3.8)M prior year; gross margin 79.3% nearly flat.","Cash, equivalents, and marketable securities $51.9M, up $3.5M from Dec 2025; $115M credit facility available.","FY2026 revenue guidance reaffirmed at $202-212M (decline 5% to 0%); adjusted EBITDA loss expected $4-6M.","CEO cites continued market share gains and case volume growth; initiated limited release of SuperBite Compression Screw System."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":47198000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":195267670.837931,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94214,"accession_number":"0001630627-26-000010","cik":1630627,"company_name":"TREACE MEDICAL CONCEPTS, INC.","ticker":"TMCI","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["2.02","7.01","5.02"],"status":"ready","headline":"Treace prelim Q1 rev $47.0-47.2M; FY26 guidance raised to $202-212M; CCO departs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q1 revenue expected $47.0-47.2M; cash $51.9M, up $3.5M from Dec 2025.","Full-year 2026 revenue guidance updated to $202-212M vs prior $200-212M.","Chief Commercial Officer Gaetano Guglielmino departed April 8; role not replaced.","CCO to consult through Jan 2027; $36,667/month fee, COBRA, prorated bonus, equity vest.","SVP Sales will now report directly to CEO John Treace."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":47198000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":195267670.837931,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106424,"accession_number":"0001193125-26-079163","cik":1630627,"company_name":"TREACE MEDICAL CONCEPTS, INC.","ticker":"TMCI","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Treace Medical Q4 revenue $62.5M (-9% YoY); guides FY2026 revenue down 0-6%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $62.5M, down 9% YoY; net loss $(9.4)M vs $(0.5)M in prior year.","FY2025 revenue $212.7M, up 2% YoY; net loss $(59.0)M vs $(55.7)M; adj. EBITDA loss $(3.9)M.","Guidance: FY2026 revenue $200-212M (decline 0-6%); adj. EBITDA loss $4-6M.","Cash used fell 46% to $27.3M in FY2025; active surgeons +6% to 3,337."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":212690000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":195267670.837931,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106423,"accession_number":"0001193125-26-011177","cik":1630627,"company_name":"TREACE MEDICAL CONCEPTS, INC.","ticker":"TMCI","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Treace Medical Q4 2025 preliminary revenue falls ~9% YoY; full year in line with guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $62.1M-$62.5M, down ~9% YoY at midpoint.","Full-year 2025 revenue $212.3M-$212.7M, ~2% YoY growth, in line with $211M-$213M guidance.","Added ~202 new active surgeons in 2025; total active surgeons ~3,337 (+6%).","Not issuing FY 2026 guidance now; will provide during Q4 earnings call on Feb 26, 2026.","CEO cites headwinds from broader economic conditions, softer consumer sentiment, product mix shift."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":212690000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":195267670.837931,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122771,"accession_number":"0001193125-25-323802","cik":1630627,"company_name":"TREACE MEDICAL CONCEPTS, INC.","ticker":"TMCI","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["1.01","1.02","2.03","3.03","7.01","8.01","9.01"],"status":"ready","headline":"Treace Medical secures $175M debt facility, refinances MidCap loans; names lead independent director","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered $175M senior secured loan: $60M term funded, $65M additional term (revenue-dependent), $50M revolver (expandable from $30M).","Proceeds used to repay $50M term and $4M revolver from MidCap loans; paid $2.3M in prepayment/exit fees.","Term loan at 1-month SOFR (floor 3%) + 5.05%; revolver at 3-month SOFR (floor 3%) + 4%; interest-only for 48 months.","Post-refinancing liquidity ~$165M; dividends restricted under loan covenants.","Board appointed John K. Bakewell as lead independent director; former CFO of Exact Sciences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":195267670.837931,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122770,"accession_number":"0001193125-25-269481","cik":1630627,"company_name":"TREACE MEDICAL CONCEPTS, INC.","ticker":"TMCI","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Treace Medical Q3 rev +11% to $50.2M; slashes FY2025 guidance to $211-213M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $50.2M (+11% YoY); net loss $(16.3)M or $(0.26)/share vs $(15.4)M loss in Q3 2024.","Adjusted EBITDA loss narrowed 49% to $(2.6)M from $(5.1)M in Q3 2024.","FY2025 revenue guidance cut to $211-213M (prev $224-230M); Adj. EBITDA loss now $6.5-7.5M (prev breakeven).","CEO cites headwinds from shift to MIS procedures, softer consumer demand, and macroeconomic conditions impacting Lapiplasty.","Director Richard W. Mott retired Nov 3; Board reduced to 7 members."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":150171000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":195267670.837931,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139457,"accession_number":"0000950170-25-105039","cik":1630627,"company_name":"TREACE MEDICAL CONCEPTS, INC.","ticker":"TMCI","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Treace Medical Q2 revenue $47.4M (+7% YoY); net loss narrows to $17.4M; FY guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $47.4M in Q2 2025, up 7% from $44.5M in Q2 2024.","Net loss $(17.4)M ($(0.28)/share) vs $(21.2)M ($(0.34)/share) a year ago; 18% improvement.","Adjusted EBITDA loss improved 58% to $(3.6)M from $(8.7)M in Q2 2024.","Total liquidity $90.7M as of June 30, 2025 ($69.3M cash plus $21.4M revolver).","Full market release of Nanoplasty, Percuplasty 3D MIS Osteotomy, and SpeedMTP Fusion Systems."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":99957000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":195267670.837931,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157039,"accession_number":"0000950170-25-075805","cik":1630627,"company_name":"TREACE MEDICAL CONCEPTS, INC.","ticker":"TMCI","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Stockholders elect directors, approve executive compensation, ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All three proposals passed at May 20, 2025 annual meeting of Treace Medical Concepts.","Directors Lawrence W. Hamilton (40.7M for, 1.6M withheld) and Deepti Jain (34.8M for, 7.5M withheld) elected.","Advisory vote on executive compensation approved: 39.9M for, 2.3M against, 15K abstain.","Ratification of Grant Thornton LLP as independent auditor for FY2025 approved: 51.4M for, 43K against, 27K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":195267670.837931,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157038,"accession_number":"0000950170-25-066915","cik":1630627,"company_name":"TREACE MEDICAL CONCEPTS, INC.","ticker":"TMCI","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Treace Q1 revenue $52.6M (+3% YoY); net loss improves to $(15.9)M; reaffirms FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $52.6M, up 3% from $51.1M; adjusted for one less selling day, growth 4.5%.","Net loss $(15.9)M ($(0.25)/share) vs $(18.7)M ($(0.30)/share) in Q1 2024, improved 15%.","Adjusted EBITDA $(3.8)M, a 53% improvement from $(8.3)M in prior-year quarter.","Reaffirms FY2025 revenue guidance $224-230M (7-10% growth) and breakeven adjusted EBITDA.","Launched three new bunion systems (Nanoplasty, Percuplasty 3D MIS, SpeedMTP MTP Fusion)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":52570000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":195267670.837931,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157037,"accession_number":"0000950170-25-051362","cik":1630627,"company_name":"TREACE MEDICAL CONCEPTS, INC.","ticker":"TMCI","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"James Treace to retire from board; CEO John Treace appointed chairman effective May 20, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James T. Treace to retire from board at 2025 annual meeting (expected May 20, 2025); departure not related to any disagreement.","Board appoints CEO & Founder John T. Treace as Chairman, effective immediately after the 2025 annual meeting.","Board size decreases from nine to eight directors upon James Treace's retirement.","Lead independent director Richard W. Mott will continue in his role.","No change in John T. Treace's compensation in connection with appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":195267670.837931,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175399,"accession_number":"0000950170-25-029009","cik":1630627,"company_name":"TREACE MEDICAL CONCEPTS, INC.","ticker":"TMCI","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Treace Medical Q4 revenue $68.7M (+10% YoY); net loss narrows to $0.5M; guides FY25 rev $224-230M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $68.7M (+10% YoY); net loss ($0.5M) vs ($6.3M) in Q4 2023; adj. EBITDA $11.1M (322% improvement).","Full-year 2024 revenue $209.4M (+12% YoY); net loss ($55.7M) vs ($49.5M); adj. EBITDA loss narrowed to ($11.0M) from ($24.4M).","FY2025 revenue guidance $224M-$230M (7-10% growth); expects breakeven adj. EBITDA for full year.","Entry into osteotomy market with Nanoplasty and Percuplasty 3D bunion systems; 280 new active surgeons added in 2024.","Cash $75.7M plus $26M revolver access; patent portfolio 97 granted, 88 pending."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":209357000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":195267670.837931,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175398,"accession_number":"0000950170-25-004578","cik":1630627,"company_name":"TREACE MEDICAL CONCEPTS, INC.","ticker":"TMCI","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Treace Medical preliminary Q4 rev ~$68.6M, FY2024 ~$209.2M, up 12% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 revenue $68.4M-$68.8M, ~10% increase at midpoint vs Q4 2023.","Full-year 2024 revenue $209.0M-$209.4M, ~12% growth at midpoint, in line with $204M-$211M guidance.","Added ~280 active surgeons in 2024; total ~3,135 active surgeons (+10% YoY), ~31% of US bunion surgeon market.","2025 financial guidance to be provided during Q4 2024 earnings call on Feb 27, 2025.","Management to present at J.P. Morgan Healthcare Conference on Jan 14, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":209357000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":195267670.837931,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192344,"accession_number":"0000950170-24-121456","cik":1630627,"company_name":"TREACE MEDICAL CONCEPTS, INC.","ticker":"TMCI","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Treace Medical Q3 revenue $45.1M (+11%), net loss improves to ($15.4M), launches Nanoplasty MIS system","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $45.1M (+11% YoY); net loss improved to ($15.4M) or ($0.25)/share from ($17.5M) loss in Q3 2023.","Adjusted EBITDA loss narrowed 45% to ($5.1M) from ($9.2M) in Q3 2023.","First entry into osteotomy market with Nanoplasty 3D Minimally Invasive Bunion Correction system; second MIS platform planned later in Q4.","Filed patent infringement suit to protect Lapiplasty technology; patent portfolio now 67 U.S. patents.","FY2024 revenue guidance revised to $204M-$211M (was $201M-$211M); expects Adjusted EBITDA loss to halve YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":140649000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":195267670.837931,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192343,"accession_number":"0000950170-24-114699","cik":1630627,"company_name":"TREACE MEDICAL CONCEPTS, INC.","ticker":"TMCI","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Treace sues Stryker for patent infringement on Lapiplasty bunion technology; reaffirms guidance","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed suit against Stryker and Wright Medical alleging infringement of 9 patents related to Lapiplasty 3D Bunion Correction.","Suit filed in U.S. District Court for the District of New Jersey; seeks injunctive relief and damages.","Treace reaffirms 2024 Adjusted EBITDA improvement of ~50% vs 2023 and expects breakeven in 2025.","John Treace, CEO, states the suit aims to protect investments in pioneering research and technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":195267670.837931,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208813,"accession_number":"0000950170-24-091777","cik":1630627,"company_name":"TREACE MEDICAL CONCEPTS, INC.","ticker":"TMCI","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Treace Medical Q2 revenue up 6% to $44.5M, net loss widens to $0.34/share, reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $44.5M (+6% YoY); gross margin 80.2% vs 81.7% prior year.","Net loss ($21.2M) or ($0.34)/share vs ($12.3M) or ($0.20)/share in Q2 2023.","Adjusted EBITDA loss ($8.7M) vs ($7.7M) a year ago; cash & equivalents $97.0M.","Full-year 2024 revenue guidance reaffirmed at $201M-$211M (7-13% growth); Adj. EBITDA expected to improve ~50%.","CEO highlights planned entry into minimally invasive metatarsal osteotomy market in Q4 2024 and 65 granted U.S. patents."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":95563000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":195267670.837931,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226594,"accession_number":"0000950170-24-063565","cik":1630627,"company_name":"TREACE MEDICAL CONCEPTS, INC.","ticker":"TMCI","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"TMCI stockholders re-elect directors and approve executive compensation at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected John K. Bakewell (39.1M for), Richard W. Mott (40.2M for), John T. Treace (44.0M for) as Class III directors.","Advisory vote on executive compensation approved: 44.8M for, 4.0M against, 13.9K abstain.","Stockholders favored holding Say-on-Pay vote every 1 year (46.7M votes); board adopted annual frequency.","Ratified Grant Thornton as independent auditor for FY2024: 52.7M for, 2.1M against, 2.6K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":195267670.837931,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226593,"accession_number":"0000950170-24-054475","cik":1630627,"company_name":"TREACE MEDICAL CONCEPTS, INC.","ticker":"TMCI","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Treace Medical Q1 revenue $51.1M (+21% YoY), cuts FY2024 guidance to $201-$211M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $51.1M (+21% YoY); net loss $18.7M ($0.30/share) vs $13.5M loss in Q1 2023.","FY2024 revenue guidance slashed to $201-$211M from $220-$225M, citing increased MIS Osteotomy competition and knockoffs.","Adjusted EBITDA loss improved to $8.3M in Q1 from $10.0M in prior year.","CEO plans two new 3D MIS Osteotomy launches later in 2024 to counter competitive headwinds.","Cash and marketable securities $112.1M; 63 granted US patents as of March 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":51108000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":195267670.837931,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}